Viridian Therapeutics, Inc. Common Stock (VRDN) is a publicly traded Healthcare sector company. As of November 9, 2026, VRDN trades at $28.93 with a market cap of $3.24B and a P/E ratio of 0.00. VRDN moved +0.00% today. Year to date, VRDN is -7.14%; over the trailing twelve months it is +3.60%. Its 52-week range spans $9.90 to $34.29. Analyst consensus is strong buy with an average price target of $41.33. Rallies surfaces VRDN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
VRDN-008 phase 1 results show 74% peak IgG reduction through eight weeks: Viridian Therapeutics reported positive phase 1 results for VRDN-008, including a 15–18-day half-life and 74% peak IgG reduction through eight weeks. The healthy-volunteer trial showed generally favorable tolerability, with no serious adverse events or dose-limiting toxicities, supporting potential dosing every eight weeks.
| Metric | Value |
|---|---|
| Price | $28.93 |
| Market Cap | $3.24B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $34.29 |
| 52-Week Low | $9.90 |
| Volume | 59.30K |
| Avg Volume | 0 |
| Revenue (TTM) | $70.85M |
| Net Income | $-342.60M |
| Gross Margin | 0.00% |
10 analysts cover VRDN: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $41.33.